Agilent Technologies A Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Agilent CrossLab | $759M+6.5% | $758M+8.9% | $755M+6.9% | $744M+7.7% | $713M+7.4% | |
| Applied Markets | $344M+14.3% | $361M+6.8% | $351M+3.8% | $324M+7.3% | $301M-1.3% | |
| Life Sciences and Diagnostics Markets | $732M+11.9% | $679M+4.9% | $755M+14.9% | $670M+14.5% | $654M+8.3% | |
| Cost of revenue by Business | ||||||
| Agilent CrossLab | $338M+6.6% | $340M+11.1% | —— | —— | $317M+7.0% | |
| Applied Markets | $152M+8.6% | $157M+4.7% | —— | —— | $140M-3.4% | |
| Life Sciences and Diagnostics Markets | $337M+9.1% | $336M+10.2% | —— | —— | $309M+10.3% | |
| Income from operations by Business | ||||||
| Agilent CrossLab | $242M+4.8% | $240M+8.6% | $246M+2.9% | $248M0.0% | $231M+6.9% | |
| Applied Markets | $80M+35.6% | $93M+10.7% | $87M+1.2% | $71M+1.4% | $59M-7.8% | |
| Life Sciences and Diagnostics Markets | $161M+24.8% | $109M-6.8% | $172M+22.0% | $118M+3.5% | $129M+12.2% | |
| Selling, General and Administrative Expense by Business | ||||||
| Agilent CrossLab | $151M+9.4% | $150M+4.9% | —— | —— | $138M+3.8% | |
| Applied Markets | $88M+11.4% | $87M+7.4% | —— | —— | $79M+1.6% | |
| Life Sciences and Diagnostics Markets | $170M+8.3% | $169M+4.3% | —— | —— | $157M+2.8% | |
| Research and Development Expense by Business | ||||||
| Agilent CrossLab | $28M+3.7% | $28M+7.7% | —— | —— | $27M+2.9% | |
| Applied Markets | $24M+4.3% | $24M+4.3% | —— | —— | $23M-2.1% | |
| Life Sciences and Diagnostics Markets | $64M+8.5% | $65M+3.2% | —— | —— | $59M-5.6% | |
| Foreign currency translation impact by Business | ||||||
| Agilent CrossLab | $1M— | $3M+175% | —— | $1M0.0% | —— | |
| Share-based compensation expense by Business | ||||||
| Agilent CrossLab | $12M+9.1% | $16M0.0% | —— | —— | $11M-8.3% | |
| Applied Markets | $6M+20.0% | $7M-12.5% | —— | —— | $5M-16.7% | |
| Life Sciences and Diagnostics Markets | $11M+22.2% | $14M-6.7% | —— | —— | $9M-21.7% | |
| Depreciation by Business | ||||||
| Agilent CrossLab | $14M0.0% | $14M0.0% | —— | —— | $14M+3.7% | |
| Applied Markets | $7M+16.7% | $6M0.0% | —— | —— | $6M+4.3% | |
| Life Sciences and Diagnostics Markets | $26M+8.3% | $26M+13.0% | —— | —— | $24M+33.3% | |
| Goodwill by Business | ||||||
| Agilent CrossLab | $1.17B+0.4% | $1.17B+0.6% | $1.17B0.0% | $1.17B+351% | $1.17B+352% | |
| Applied Markets | $315M+2.3% | $316M+3.9% | $309M0.0% | $309M— | $308M— | |
| Life Sciences and Diagnostics Markets | $3B-0.1% | $3B+1.2% | $3B-0.1% | $3B— | $3B— | |
| Net revenue by Product | ||||||
| Instrumentation | $618M+12.4% | $658M+5.3% | $653M+5.3% | $599M+7.7% | $550M+0.4% | |
| Non-Instrumentation and Other | $1.22B+8.9% | $1.14B+8.0% | $1.21B+11.7% | $1.14B+11.4% | $1.12B+9.1% | |
| Services and Other | $530M+10.0% | $525M+9.1% | $533M+10.1% | $508M+11.2% | $482M+7.6% | |
| Net revenue by Geography | ||||||
| Americas | $764M+12.7% | $678M+1.3% | $776M+14.1% | $683M+9.1% | $678M+6.4% | |
| Asia Pacific | $553M+0.9% | $602M+9.7% | $559M-1.4% | $563M+8.3% | $548M+7.5% | |
| Europe | $518M+17.2% | $518M+11.9% | $526M+15.9% | $492M+13.9% | $442M+3.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Agilent Technologies break its business down?
- Agilent Technologies (A) reports net revenue by business across 3 parts — Agilent CrossLab, Applied Markets and Life Sciences and Diagnostics Markets. Each is extracted from the segment footnotes and tracked over time.
- Where does Agilent Technologies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Agilent Technologies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
